Campbell & CO Investment Adviser LLC Arvinas, Inc. Transaction History

Campbell & CO Investment Adviser LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$24.46 - $40.4 $197,025 - $325,422	8,055 Added 20.03%	48,271 $1.28 Million
Q1 2024 May 10, 2024	BUY	$36.38 - $52.31 $1.46 Million - $2.1 Million	40,216 New	40,216 $1.66 Million
Q2 2023 Aug 11, 2023	BUY	$21.73 - $31.43 $416,585 - $602,544	19,171 New	19,171 $475,000
Q2 2022 Aug 09, 2022	SELL	$36.01 - $74.24 $129,636 - $267,264	-3,600 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$60.27 - $81.57 $427,917 - $579,147	-7,100 Reduced 66.36%	3,600 $242,000
Q4 2021 Feb 10, 2022	BUY	$65.85 - $96.21 $342,419 - $500,291	5,200 Added 94.55%	10,700 $879,000
Q3 2021 Nov 10, 2021	BUY	$73.2 - $107.87 $402,600 - $593,285	5,500 New	5,500 $452,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.